Cambridge tests first AI-designed vaccine in humans

Researchers at the University of Cambridge have tested the world's first vaccine with an active ingredient designed entirely by artificial intelligence. The experimental vaccine aims to protect against multiple coronaviruses at once, including variants that don't exist yet.

Thirty-nine healthy volunteers received the vaccine in trials across two UK medical centers. The results showed no major side effects and triggered immune responses against SARS-CoV-2, the original SARS virus, and related bat viruses that could jump to humans in the future.

How does it work?

The team fed their AI model genetic data from coronaviruses in the Sarbeco family, which includes the virus that caused COVID-19. The AI analyzed these sequences and designed an antigen containing features shared across the entire virus group.

"We've converted vaccine development from being reactive to being future proof," said Professor Jonathan Heeney from Cambridge's Department of Veterinary Medicine. "Our vaccines will continue to provide protection against viruses even as they mutate into new strains."

The approach creates what researchers call a "super-antigen" that recognizes common elements across multiple related viruses. This means it could work against:

• Current coronavirus variants
• Future mutations of existing viruses
• Completely new viruses from the same family

Why does it matter?

Traditional vaccines play catch-up with viruses. Scientists develop them after outbreaks start, then struggle to keep pace as viruses mutate. This reactive approach left the world vulnerable during COVID-19's early months.

An AI-designed universal vaccine could change that dynamic entirely. Instead of chasing viral mutations, scientists could deploy broad-spectrum protection before pandemics begin. The same approach could work for other virus families that cause flu, Ebola, and other diseases that jump between humans.

"We've overcome the problem of traditional vaccines, which have limited protection," Heeney explained. "It means we can escape the constant cycle of chasing the virus variants circulating in humans and updating the vaccines to try to catch up, like a dog chasing its tail."

The context

AI has already proven valuable in medical research, from drug discovery to diagnostic imaging. But this marks the first time a completely AI-designed vaccine component has reached human trials. The technology could speed up pandemic preparedness significantly.

The trial's small size means larger studies will follow with more diverse participants. Researchers need to confirm the vaccine's effectiveness across different populations and age groups before it could reach the public.

This breakthrough comes as scientists worldwide work to prevent future pandemics. The approach could be adapted for other virus families, potentially creating a new category of preemptive vaccines that protect against threats before they emerge.